Can digital mobility assessment enhance the clinical assessment of disease severity in Parkinson's disease?

Kirk, Cameron; Rehman, Rana Zia Ur; Galna, Brook; Alcock, Lisa; Ranciati, Saverio; Palmerini, Luca; García Aymerich, Judith; Hansen, Clint; Schaeffer, Eva; Berg, Daniela; Maetzler, Walter; Rochester, Lynn; Del Din, Silvia; Yarnall, Alison J.

doi:http://dx.doi.org/10.3233/JPD-230044

Can digital mobility assessment enhance the clinical assessment of disease severity in Parkinson's disease?

License

Citation

Kirk C, Zia Ur Rehman R, Galna B, Alcock L, Ranciati S, Palmerini L, Garcia-Aymerich J, Hansen C, Schaeffer E, Berg D, Maetzler W, Rochester L, Del Din S, Yarnall AJ. Can digital mobility assessment enhance the clinical assessment of disease severity in Parkinson's disease?. J Parkinsons Dis. 2023;13(6):999-1009. DOI: 10.3233/JPD-230044

Abstract

Background: Real-world walking speed (RWS) measured using wearable devices has the potential to complement the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS III) for motor assessment in Parkinson's disease (PD). Objective: Explore cross-sectional and longitudinal differences in RWS between PD and older adults (OAs), and whether RWS was related to motor disease severity cross-sectionally, and if MDS-UPDRS III was related to RWS, longitudinally. Methods: 88 PD and 111 OA participants from ICICLE-GAIT (UK) were included. RWS was evaluated using an accelerometer at four time points. RWS was aggregated within walking bout (WB) duration thresholds. Between-group-comparisons in RWS between PD and OAs were conducted cross-sectionally, and longitudinally with mixed effects models (MEMs). Cross-sectional association between RWS and MDS-UPDRS III was explored using linear regression, and longitudinal association explored with MEMs. Results: RWS was significantly lower in PD (1.04 m/s) in comparison to OAs (1.10 m/s) cross-sectionally. RWS significantly decreased over time for both cohorts and decline was more rapid in PD by 0.02 m/s per year. Significant negative relationship between RWS and the MDS-UPDRS III only existed at a specific WB threshold (30 to 60 s, β= - 3.94 points, p = 0.047). MDS-UPDRS III increased significantly by 1.84 points per year, which was not related to change in RWS. Conclusion: Digital mobility assessment of gait may add unique information to quantify disease progression remotely, but further validation in research and clinical settings is needed.